Clinical Trials Browser

Phase 3 × Withdrawn × Plasma cell × Clear all

NCT04288765 2021-07-09

Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Phase 3 Withdrawn

Multiple Myeloma

NCT02155634 2018-04-10

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Phase 3 Withdrawn

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias